0.8400 +0.07 (9.08%)
After hours: 4:55PM EDT
|Bid||0.7700 x 4000|
|Ask||0.8888 x 1200|
|Day's Range||0.7700 - 0.9500|
|52 Week Range||0.6610 - 3.2700|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / May 3, 2018 / There was no catalyst or news to send shares of both Midatech and Eleven Biotherapeutics higher on Wednesday. Midatech Pharma Plc shares closed up 10.56% yesterday with more gains seen in after-hours trading as well. There was no significant news from the specialty pharmaceutical company to explain the move up.
Midatech Pharma Plc (MTP) is a specialty pharmaceutical company with three novel drug delivery technologies. The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The gold nanoparticle (GNP) technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use.
Examining how Münchener Tierpark Hellabrunn AG (MUN:MTP) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple senseRead More...
15 March 2018 Midatech Pharma PLC. Midatech announces changes in Senior Management Team. Midatech, the international specialty pharmaceutical company focused on developing and commercialising products ...
On January 16, 2018, Midatech Pharma Plc (MTP) announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug (IND) application to initiate a clinical trial of MTX110 in patients with diffuse intrinsic pontine glioma (DIPG). The active compound in MTX110 is the poorly soluble hydroxamic acid drug panobinostat, a histone deacetylase inhibitor (HDACi), which until recently could not be formulated for parenteral administration.
28 February 2018 Midatech Pharma PLC. Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency. Midatech, the international specialty pharmaceutical company focused on developing ...
On January 9, 2018, Midatech Pharma Plc (MTP) announced that Polish regulators have given approval to initiate the company’s first in-human clinical trial of Q-Octreotide (MTD201). Q-Octreotide is the sustained release (SR) version of octreotide, an octapeptide that mimics naturally occurring somatostatin. Octreotide is an existing, immediate- and sustained- release injection product used to decrease the production of growth hormone in people suffering from acromegaly and for the treatment of neuroendocrine (hormone secreting) tumors (NET).
We are initiating coverage of Midatech Pharma Plc (NASDAQ:PLC) with a $6.00 valuation. MIdatech is a U.K. based international specialty pharmaceutical company focused on oncology and other therapeutic areas. The company has three proprietary drug delivery technologies: Q-Sphera for sustained release of already marketed products, Midacore gold nanoparticles (GNP) for targeted delivery, and Nano Inclusion (NI) for local delivery.
Midatech Pharma Plc (AIM:MTPH), a biotechnology company based in United Kingdom, saw significant share price volatility over the past couple of months on the AIM, rising to the highs ofRead More...